Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 2013. The report specifically addresses a notification of transactions involving directors and connected persons, rather than providing comprehensive financial results for the period.
Key Financial Metrics
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notification regarding share transactions and does not contain financial statements.
Material Changes
No material financial changes versus prior periods are reported in this filing. The document details a specific change in share ownership for a director:
- Sir Andrew Witty: Transferred 500 Ordinary Shares to each of his two children and gifted 40 Ordinary Shares.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly complies with Disclosure Rule 3.1.4R(1)(a) and (c) regarding the notification of director transactions.
Key Facts for Investor Verification
- Director Sir Andrew Witty reduced his direct holding by 1,040 Ordinary Shares (1,000 transferred to children, 40 gifted) on March 18, 2013.
- This filing is a compliance notification and does not include quarterly or annual financial performance data.
- Investors should refer to the company's Form 20-F or other earnings releases for financial metrics.